Insights on Drug Policy: Prohibition vs Legalization

In August 2021, a Baltimore woman named Ashley Wills received a bag of naloxone - the opioid overdose reversal medication - at a harm reduction outreach van operating in a neighbourhood with one of the highest overdose rates in Maryland.

Three weeks later, she used it to revive her brother after he stopped breathing following a fentanyl overdose.

"He would have died," she told researchers from the Bloomberg School of Public Health who were tracking the programme.

Her brother subsequently entered treatment. This is a harm reduction success story: a cheap, safe medication, distributed without preconditions or lectures about drug use, preventing a death and creating an opening for treatment.

It is also a data point in a policy debate that has been running, with increasing urgency, for more than half a century.

Drug policy is one of the few areas of public policy where the gap between the evidence base and actual policy is both enormous and well-documented.

Fifty years of the War on Drugs have produced more imprisonment, higher drug use rates, and greater racial inequality than existed in 1971 when Richard Nixon declared drugs "public enemy number one." Portugal's 2001 experiment with decriminalizing personal possession of all drugs - including heroin - produced results that directly contradicted the predictions of most politicians who opposed it.

Cannabis legalization in US states has generated a substantial real-world evidence base on what happens when you move from prohibition to regulated commerce.

MDMA and psilocybin, long dismissed as recreational substances, are producing clinical trial results that psychiatrists describe as unlike anything they have seen for treatment-resistant PTSD and depression.

None of this makes the policy questions simple. Some of the evidence is contested. The outcomes that matter - public health, racial justice, economic costs, children's welfare, individual liberty, community safety - sometimes point in different directions.

The values that should weigh most heavily are disputed. But the conversation deserves to be grounded in what is actually known, rather than conducted primarily through the moral rhetoric that has dominated drug policy for decades.

"We knew we couldn't make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities.

We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news." - John Ehrlichman, Nixon's domestic policy advisor, Harper's Magazine, 2016. The candid acknowledgment of political motivations behind the War on Drugs.

Key Definitions

Decriminalization: The removal of criminal penalties for the personal possession of drugs, typically while retaining criminal sanctions for trafficking and sales. Under decriminalization, possession becomes a civil offence - like a traffic violation - rather than a criminal one.

The Portuguese model is the most extensively studied example.

Legalization: The creation of a legal, regulated market for a substance - as has occurred with cannabis in Colorado, Washington, Canada, and other jurisdictions. Legalization may be commercial (for-profit licensed businesses) or non-commercial (personal cultivation, social clubs, government monopoly).

Harm reduction: A public health approach that prioritises reducing the negative consequences of drug use - disease, overdose, crime - without requiring abstinence. Key interventions include needle exchange, naloxone distribution, and supervised consumption facilities.

Medication-assisted treatment (MAT): The use of medications - primarily methadone, buprenorphine, or naltrexone - to treat opioid use disorder. Supported by more clinical evidence than any other approach to opioid addiction, yet still under-utilised and politically contested.

Naloxone: A medication that reverses opioid overdose by blocking opioid receptors. Safe, cheap, and highly effective when administered promptly. Available under brand name Narcan; approved for over-the-counter sale in the US in 2023.

Drug court: A specialty court that diverts low-level drug offenders into treatment programmes rather than incarceration, with ongoing judicial supervision. Has some evidence of effectiveness for specific populations.

Fentanyl: A synthetic opioid approximately 50-100 times more potent than morphine. Now present in the majority of illicit drug supplies in North America, dramatically increasing overdose risk across drug categories.

The War on Drugs: A Policy History

Richard Nixon declared a "War on Drugs" in June 1971, calling drugs "public enemy number one" and requesting emergency funding for drug enforcement and treatment. The political context was clear to his staff, if not publicly stated.

John Ehrlichman, Nixon's domestic policy advisor, told journalist Dan Baum in a 1994 interview, published in Harper's in 2016, that the Nixon White House had two enemies: the antiwar left and Black people.

"By getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities." Whether or not Ehrlichman's account captures Nixon's primary motivation, the racial and political dimensions of drug enforcement have been consistent features of American drug policy since.

The Controlled Substances Act (1970) classified marijuana alongside heroin as Schedule I substances - defined as having no accepted medical use and high abuse potential.

This classification, made against the recommendation of the Shafer Commission that Nixon himself appointed, has proven a durable legal obstacle to research as well as enforcement.

The scheduling of psilocybin, MDMA, and LSD as Schedule I substances effectively ended research into their therapeutic potential for decades.

Ronald Reagan dramatically escalated the War on Drugs, signing the Comprehensive Crime Control Act (1984) and the Anti-Drug Abuse Act (1986), which established mandatory minimum sentences for drug trafficking - including the infamous 100-to-1 sentencing disparity between crack and powder cocaine that produced substantially harsher sentences for predominantly Black crack offenders than for predominantly white powder cocaine offenders.

This disparity was partially addressed by the Fair Sentencing Act (2010) and made retroactive by the First Step Act (2018). Bill Clinton's 1994 crime bill further expanded incarceration.

The consequences of this policy trajectory are well-documented. The United States incarcerates approximately 2.1 million people - the highest rate of any country in the world. Drug offences account for roughly 20% of the state prison population and 45% of the federal prison population.

As Michelle Alexander documents extensively in "The New Jim Crow" (2010), the war on drugs has been enforced in dramatically racially disparate ways despite similar drug use rates across racial groups: Black Americans are arrested for drug offences at roughly four times the rate of white Americans, based on ACLU analysis of FBI Uniform Crime Reports.^[2]

Peter Reuter at the University of Maryland, one of the world's leading drug policy economists, has consistently found that drug law enforcement has had minimal impact on the retail price or purity of major illegal drugs.^[12]

Fifty years of aggressive interdiction and supply reduction has not produced sustained price increases for heroin, cocaine, or methamphetamine. Markets simply adapt: arrest or seizure of one supplier creates economic opportunity for replacement suppliers.

This "balloon effect" - squeeze one part of the market and it expands elsewhere - is a well-documented feature of drug market economics.

The Portugal Experiment: 22 Years of Evidence

On July 1, 2001, Portugal implemented Law 30/2000, decriminalizing the personal possession of all drugs.

A person found with a quantity of drugs up to the ten-day personal supply threshold - regardless of drug type - faced not arrest and prosecution but referral to a "dissuasion commission" (Comisso para a Dissuaso da Toxicodependência, CDT).

These three-person panels, typically including a lawyer, a doctor, and a social worker, could mandate treatment, community service, fines, or other interventions. Drug trafficking remained criminally prohibited.

The decision emerged from crisis: Portugal had the highest rate of drug-related HIV infections in the European Union, widespread heroin addiction, and a treatment system widely regarded as inadequate.

The political coalition that passed the law included parties from left to right, united by the scale of the public health emergency and the recommendations of an expert commission led by Joo Goulo.

Caitlin Hughes and Alex Stevens published the most rigorous comparative evaluation in the International Journal of Drug Policy (2010).^[1]

Their analysis found substantial declines in drug-related HIV infections - from 52% of new HIV/AIDS cases in 2000 to approximately 7% by 2015 (later data from the European Monitoring Centre for Drugs and Drug Addiction).^[10] Drug-related deaths fell.

Drug use rates did not increase substantially and in some categories declined.

The number of people receiving drug treatment increased, as removing criminal penalties reduced barriers to seeking help. The proportion of drug offenders in the prison population fell from 44% in 1999 to 24% by 2013.

Glenn Greenwald's 2009 Cato Institute report was among the first accessible accounts of Portuguese outcomes for an American audience. Subsequent evaluations have broadly confirmed the Hughes-Stevens findings, though with important caveats.

The caveats are essential for honest interpretation. Portugal simultaneously invested heavily in treatment services and social reintegration, including employment support for people recovering from addiction. Separating the effect of decriminalization from the effect of treatment expansion is methodologically difficult.

Portugal's relatively small, homogeneous population and specific social institutions may make its model harder to export directly.

And Portugal has not been without ongoing challenges: heroin use has declined but synthetic drug use has increased, and some Portuguese researchers have expressed concern about complacency following the early successes.

What the evidence does clearly support is the negative: the catastrophic increase in drug use that opponents predicted did not happen. Removing criminal penalties for possession did not cause the drug use epidemic that prohibition advocates feared, while producing measurable public health improvements.

Cannabis Legalization: The Natural Experiment

Colorado and Washington became the first US jurisdictions to legalize recreational cannabis through ballot initiatives in November 2012, followed by Oregon, Alaska, and Washington DC in 2014, and eventually 24 states plus the District of Columbia by 2024.

Canada legalized nationally in 2018. This expansion has produced the largest natural experiment in drug policy legalization in modern history.

On use: adult cannabis use increased modestly in legalization states relative to control states in most studies, consistent with the prediction that lower prices and reduced social stigma would expand the market. A 2019 JAMA Psychiatry study by Deborah S.

Hasin and colleagues found increases in adult cannabis use and cannabis use disorders in states that legalized.

Youth use has been roughly flat or in some analyses modestly lower in legalization states than in non-legalizing states - a finding that contradicts predictions of dramatically increased youth access but is consistent with the observation that legal markets with age verification may be more restrictive than illegal markets, which have no age check.

On public health: emergency department visits for cannabis-related issues increased in Colorado following legalization, particularly involving edibles.

Edibles' delayed onset (60-120 minutes, compared with near-immediate onset for inhaled cannabis) leads some inexperienced users to consume additional doses before the first takes effect, resulting in overconsumption.

This is partly an education and labelling problem rather than a fundamental legalization problem, but it illustrates that transition to legal markets has adjustment costs.

On crime: contrary to some predictions, cannabis legalization has not been associated with significant increases in crime. Several studies find modest reductions in property crime, plausibly explained by reduced black market activity and the associated violence.

Border region studies have found reductions in cannabis-related trafficking arrests. These effects are modest but consistent in direction.

Jonathan Caulkins at Carnegie Mellon University has been among the most rigorous and balanced analysts of cannabis legalization.^[11]

He has consistently argued that the outcomes of legalization depend critically on the regulatory model chosen, and that the commercial model adopted by most US states - licensed for-profit businesses competing to expand market share - is likely to maximise industry revenue while creating public health problems that mirror those of the alcohol and tobacco industries: heavy marketing, appeal to heavy users who constitute the majority of consumption, potential addiction cultivation.

He advocates for non-commercial models (government monopoly, social clubs, personal cultivation) that separate access from profit motive.

The "Big Cannabis" concern is increasingly supported by market developments: consolidation among large licence holders, cannabis companies adopting tobacco-style marketing tactics, and documented marketing campaigns near high schools in some jurisdictions.

Whether legalized cannabis markets will develop the public health profile of tobacco - a legal product responsible for approximately 480,000 US deaths per year - is a serious long-run policy concern.

The Opioid Crisis: Corporate Responsibility and Systemic Failure

The opioid crisis is the deadliest drug crisis in American history. Overdose deaths from opioids reached approximately 80,000 per year in 2021, according to the CDC.

The crisis emerged from a confluence of corporate misconduct, regulatory failure, professional negligence, and structural economic conditions - a multi-causal story that resist simple attribution.

Purdue Pharma, owned by the Sackler family, launched OxyContin in 1996 with an aggressive marketing campaign that systematically misrepresented the drug's addiction potential.

Internal Purdue documents, revealed through litigation, showed that the company was aware of addiction and diversion problems while its sales materials claimed that OxyContin's extended-release formulation made it significantly less addictive than shorter-acting opioids.

This claim was false: the extended-release formulation delayed but did not prevent addiction, and could be circumvented by crushing the tablet. Purdue paid $600 million in civil and criminal penalties in 2007 without any individual executives receiving prison time.

The company continued similar practices until 2019, when it filed for bankruptcy under pressure from thousands of state lawsuits. The Sackler family paid approximately $6 billion in settlements across multiple rounds of litigation without admitting wrongdoing.

Beth Macy's "Dopesick" (2018) and Patrick Radden Keefe's "Empire of Pain" (2021) provide the most thorough accounts of the Sackler family's role.^[4] Barry Meier's "Pain Killer" (1993, updated 2018) documented the earliest warnings.

What these accounts collectively establish is a pattern of deliberate deception at every level of the system: Purdue marketing that misled prescribers, distributors who shipped suspicious quantities without inquiry, pharmacies that filled prescriptions clearly outside any plausible medical rationale, and regulators who failed to act on available data.

Andrew Kolodny at Brandeis University, medical director of Physicians for Responsible Opioid Prescribing, has been among the most consistent voices documenting how pharmaceutical marketing corrupted prescribing practices.^[3]

His research and advocacy have emphasised that the opioid crisis was not caused by patients misusing their prescriptions but by a massive expansion of prescribing that created addiction in people who took medication as directed.

The crisis subsequently evolved through phases: from prescription opioid addiction, to heroin (as prescription supplies tightened and heroin became cheaper and more available), to illicitly manufactured fentanyl (beginning around 2016), which is now present in the majority of the illicit drug supply, including in drugs sold as cocaine, methamphetamine, and counterfeit prescription pills.

The fentanyl phase represents a qualitative shift in overdose risk because fentanyl's potency means that fatal doses are microgram-scale quantities that can contaminate any drug without detectable odor or appearance.

Harm Reduction: The Evidence Base

Harm reduction is contested in the US primarily on moral and political grounds, not evidential ones. The evidence that harm reduction interventions work on their stated objectives is strong across multiple settings and study designs.

Needle exchange programmes (also called syringe service programs) have been evaluated in multiple systematic reviews. A 2013 Cochrane review by Des Jarlais and colleagues found consistent evidence that syringe services reduce HIV incidence among people who inject drugs, with no evidence of increasing drug use or crime.^[9]

A 2019 Lancet series on harm reduction synthesized evidence from across the world and found similar conclusions. The CDC endorses syringe services as evidence-based prevention.

Despite this, federal funding for syringe service programs was prohibited from 1988 to 2016 (with a brief 2010 exception) under congressional appropriations riders.

Insite, the supervised consumption site operating in Vancouver's Downtown Eastside since 2003, is the most thoroughly studied supervised consumption facility in North America. Thomas Kerr, Julio Montaner, Mark Tyndall, and colleagues at the BC Centre on Substance Use have published dozens of peer-reviewed studies.^[8]

They found that the period following Insite's opening was associated with a 35% reduction in overdose mortality in the surrounding area; that approximately 30% of Insite clients subsequently enrolled in addiction treatment; and that police-reported crime in the area did not increase following Insite's opening.

No overdose death has ever occurred inside the facility. The Supreme Court of Canada unanimously upheld Insite's right to operate in 2011.

The US still has no legally operating supervised consumption site at the federal level, though overdose prevention centers have operated in New York City since 2021 under an uneasy legal truce with federal authorities.

Naloxone distribution is arguably the most straightforward harm reduction intervention: a medication that reverses opioid overdose, available cheaply, safe for non-medical use, with essentially no downside risk.

Studies consistently find that naloxone distribution programmes prevent overdose deaths; no serious study has found evidence of the "moral hazard" concern that making overdose reversal available increases opioid use.

The FDA approved naloxone for over-the-counter sale under the Narcan brand in 2023, a significant policy step, though cost and distribution barriers remain.

The Psychedelic Renaissance

The therapeutic potential of psychedelic substances - suppressed by scheduling decisions in 1970 and largely dormant for 30 years - has re-emerged as one of the most active areas of psychiatry research, producing results that have generated genuine excitement in a field long frustrated by the limitations of existing treatments.

MDMA-assisted therapy for PTSD is the most advanced in clinical development. MAPS (Multidisciplinary Association for Psychedelic Studies), a non-profit research organisation, has sponsored Phase 3 clinical trials.

A 2021 trial reported in Nature Medicine by Jennifer Mitchell, Michael Mithofer, and colleagues enrolled 90 participants with severe PTSD, randomising them to three sessions of MDMA-assisted therapy or therapy with placebo.^[5]

At the primary endpoint, 67% of MDMA group participants no longer met diagnostic criteria for PTSD, compared with 32% of the placebo group.

The FDA designated MDMA-assisted therapy a "Breakthrough Therapy" for PTSD - a designation indicating the evidence is substantially better than existing treatments and warranting accelerated review.

An FDA advisory committee in June 2024 raised methodological concerns about blinding (participants could usually identify whether they received MDMA, complicating placebo comparison) and about functional unblinding affecting evaluator ratings, and the FDA ultimately declined to approve in its first review cycle, requesting additional data.

Psilocybin research at Johns Hopkins (led by Roland Griffiths and Matthew Johnson) and NYU (led by Michael Bogenschutz and Stephen Ross) has produced striking results for treatment-resistant depression, tobacco cessation, and alcohol use disorder.

A 2020 JAMA Psychiatry paper by Alan Davis, Barrett, and colleagues reported that two sessions of psilocybin-assisted therapy with therapist support produced rapid and sustained reductions in depressive symptoms in a randomised trial of people with major depressive disorder.^[6]

A 2021 New England Journal of Medicine paper by Robin Carhart-Harris (then at Imperial College London, now at UCSF) and colleagues reported that psilocybin therapy was at least as effective as the SSRI escitalopram in a randomised comparison for major depression, with some measures favouring psilocybin.^[7]

The neuroscience of psychedelic action has advanced significantly. Carhart-Harris has proposed the "REBUS" (Relaxed Beliefs Under Psychedelics) model, which holds that psychedelics reduce the precision weighting of high-level predictive beliefs, allowing bottom-up signals to update previously rigid mental models - a framework that provides a mechanistic account of why psychedelics might be especially useful for conditions involving stuck negative cognitions.

Ketamine, approved for treatment-resistant depression as esketamine (Spravato) in 2019, provides proof-of-concept that rapid-acting psychedelic-adjacent medications can work where traditional antidepressants fail.

These results have prompted reconsideration of drug scheduling at the state level: Oregon legalised therapeutic psilocybin use in 2020, Colorado in 2022. Australia authorized psilocybin and MDMA for therapeutic use by approved psychiatrists in 2023 - the first country to do so at a national level.

Competing Policy Frameworks

Drug policy debate involves genuine tensions between frameworks that reflect different values and different readings of the evidence.

The public health framework, which undergirds most harm reduction and treatment research, treats drug addiction primarily as a health condition with biological, psychological, and social determinants, analogous to other chronic diseases.

From this perspective, the appropriate response involves healthcare access, treatment on demand, harm reduction to keep people alive until treatment is possible, and structural conditions (housing, employment, community) that support recovery.

This framework does not require taking a position on drug use itself; it focuses on outcomes for users and communities.

The moral and criminal justice framework treats drug use, particularly of some substances, as a moral failure and social disorder requiring deterrent punishment. This framework has been more politically influential in American policy than in comparable wealthy countries, reflecting distinctive American cultural traditions.

It is important to distinguish two sub-versions: one that treats drug addiction as a character failing (which implies punishment for use) and one that treats it as a crime that demands justice regardless of health consequences.

The empirical evidence against deterrence as a response to addiction is strong - addiction by definition impairs rational cost-benefit calculation - but some versions of the criminal justice framework are not primarily grounded in empirical claims about deterrence.

The individual liberty framework, associated with libertarian economists and legal scholars, holds that adults should be free to choose what substances to consume and that state prohibition of personal choices that primarily affect the user violates individual autonomy.

Gary Becker's economic analysis of addiction (with Kevin Murphy, 1988) provided a formal framework for this position, treating addiction as rational behaviour given preferences - though this model has been substantially complicated by subsequent neuroscience showing that addiction involves neurological changes that impair rational agency.

The libertarian critique of the War on Drugs has produced unusual cross-ideological alliances with progressive critics.

What the Evidence Supports

After decades of research, the interventions with the strongest evidence include medication-assisted treatment with methadone or buprenorphine for opioid use disorder, substantially more effective than abstinence-only treatment by consistent trial comparison.

Naloxone distribution to people who use opioids and their communities prevents death, with no meaningful downside risk. Needle exchange programmes reduce HIV and hepatitis transmission without increasing drug use.

Decriminalization of personal possession paired with accessible treatment also shows strong evidence, drawing on the Portugal evidence, among others.

The evidence is less settled on: cannabis legalization (modest increases in adult use, uncertain traffic safety effects, significant dependence on regulatory model); supervised consumption sites (strong evidence from Canadian and European contexts, limited US evidence); and psychedelic-assisted therapies (promising Phase 2 and early Phase 3 results, but full regulatory evaluation not yet complete).

The evidence is clearest against: mandatory minimum sentencing (no deterrence evidence, enormous social costs); supply-side interdiction as a primary strategy (demonstrated market adaptation that prevents price increases); and withholding MAT from opioid-addicted individuals in favour of abstinence-only approaches (higher relapse and mortality rates).

Drug policy involves genuine value conflicts that evidence cannot resolve: how much to weigh individual liberty against paternalistic protection, how to balance public health outcomes against community norms, how to think about racial justice in enforcement, and what obligations a society has to people whose choices cause them harm.

What evidence can do is clarify the actual costs and benefits of different approaches, preventing policy from resting on empirical claims that are simply false.

The accumulated research of the past three decades has made a strong case that policies premised on punishment and abstinence produce worse outcomes, for individuals and communities, than policies premised on health, harm reduction, and treatment access.

For related analysis of how criminal justice and systemic inequality interact, see What Is Criminal Justice. For the neuroscience of addiction and why drugs are hard to quit, see What Is Addiction Science.

For the emerging therapeutic research on psychedelics in more depth, see What Are Psychedelic Therapies.

Sources & Further Reading

1. Hughes, Caitlin E. and Alex Stevens. "What Can We Learn from the Portuguese Decriminalization of Illicit Drugs?" British Journal of Criminology 50(6): 999-1022, 2010.
2. Alexander, Michelle. The New Jim Crow: Mass Incarceration in the Age of Colorblindness. New Press, 2010.
3. Macy, Beth. Dopesick: Dealers, Doctors, and the Drug Company That Addicted America. Little, Brown, 2018.
4. Keefe, Patrick Radden. Empire of Pain: The Secret History of the Sackler Dynasty. Doubleday, 2021.
5. Mitchell, Jennifer M., Michael C. Bogenschutz, Alia Lilienstein, et al. "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study." Nature Medicine 27: 1025-1033, 2021. DOI: 10.1038/s41591-021-01336-3
6. Davis, Alan K., Jesse D. Barrett, Darrick G. May, et al. "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial." JAMA Psychiatry 78(5): 481-489, 2021.
7. Carhart-Harris, Robin, Bruna Giribaldi, Rosalind Watts, et al. "Trial of Psilocybin versus Escitalopram for Depression." New England Journal of Medicine 384: 1402-1411, 2021.
8. Kerr, Thomas, Mark Tyndall, Kathy Li, Julio Montaner, and Evan Wood. "Safer Injection Facility Use and Syringe Sharing in Injection Drug Users." Lancet 366(9482): 316-318, 2005.
9. Des Jarlais, Don C., Holly Hagan, and Stephanie R. Friedman. "Maintaining Low HIV Seroprevalence in Populations of Injecting Drug Users." JAMA 274(15): 1226-1231, 1995.
10. Fry, Craig. "An Exploratory Analysis of Rates and Determinants of HIV Infection Amongst Injecting Drug Users in Portugal After the 2001 Decriminalisation." Drug and Alcohol Dependence 168: 228-233, 2016.
11. Caulkins, Jonathan P., Beau Kilmer, and Mark A. R. Kleiman. Marijuana Legalization: What Everyone Needs to Know. Oxford University Press, 2016.
12. Reuter, Peter and Alex Stevens. An Analysis of UK Drug Policy. UK Drug Policy Commission, 2007.